Inlyta (axitinib) — United Healthcare
relapsed or stage IV renal cell carcinoma
Initial criteria
- Diagnosis of advanced renal cell carcinoma AND (patient has failed one prior systemic therapy OR Inlyta will be used in combination with Bavencio (avelumab) or Keytruda (pembrolizumab))
- OR Diagnosis of relapsed or stage IV renal cell carcinoma
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Inlyta therapy
Approval duration
12 months